The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Bareon     1-ethyl-6,8-difluoro-7-(3- methylpiperazin...

Synonyms: LFLX, lomefloxacin, Lomefloxacine, Lomefloxacino, Lomefloxacinum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Bareon


High impact information on Bareon


Chemical compound and disease context of Bareon


Biological context of Bareon


Anatomical context of Bareon


Associations of Bareon with other chemical compounds


Gene context of Bareon

  • Interestingly, p21CIP1/WAFI protein was upregulated by lomefloxacin in the dark by a p53-independent mechanism [21].
  • Lomefloxacin could also lead to apoptosis in keratinocytes exposed to ultraviolet A: caspase-3 was activated and FAS-L gene was induced [17].
  • The phototumorigenic fluoroquinolone, lomefloxacin, photosensitises p53 accumulation and transcriptional activity in human skin cells [21].
  • Our data show that lomefloxacin once-daily induces high and sustained concentrations in the various potential sites of pulmonary infection and clearly indicate that the pharmacokinetic behavior of this fluoroquinolone permits once-daily administration in patients with acute exacerbations of COPD [22].
  • Block of pancreatic beta-cell K(ATP) currents could be mediated by interaction of lomefloxacin either with the regulatory subunit (SUR1) or with the pore-forming subunit (Kir6.2) [23].

Analytical, diagnostic and therapeutic context of Bareon


  1. Fluoroquinolone (Lomefloxacin) International Surveillance Trial: a report of 30 months of monitoring in vitro activity. Jones, R.N. Am. J. Med. (1992) [Pubmed]
  2. A multicenter study of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated acute pyelonephritis. Mouton, Y., Ajana, F., Chidiac, C., Capron, M.H., Home, P., Masquelier, A.M. Am. J. Med. (1992) [Pubmed]
  3. Lomefloxacin: microbiologic assessment and unique properties. Mayer, K.H., Ellal, J.A. Am. J. Med. (1992) [Pubmed]
  4. A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology. Kemper, P., Köhler, D. Am. J. Med. (1992) [Pubmed]
  5. Diagnosis and interventions in lower respiratory tract infections. Wijnands, G.J. Am. J. Med. (1992) [Pubmed]
  6. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. Cox, C.E. Am. J. Med. (1992) [Pubmed]
  7. Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing. Mant, T.G. Am. J. Med. (1992) [Pubmed]
  8. The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone. Rizk, E. Am. J. Med. (1992) [Pubmed]
  9. Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults. Iravani, A. Am. J. Med. (1992) [Pubmed]
  10. Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis. Gotfried, M.H., Ellison, W.T. Am. J. Med. (1992) [Pubmed]
  11. Infection in the elderly: studies with lomefloxacin. Crome, P., Bruce-Jones, P. Am. J. Med. (1992) [Pubmed]
  12. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Greenberg, R.N., Newman, M.T., Shariaty, S., Pectol, R.W. Antimicrob. Agents Chemother. (2000) [Pubmed]
  13. Fluoroquinolones: place in ocular therapy. Smith, A., Pennefather, P.M., Kaye, S.B., Hart, C.A. Drugs (2001) [Pubmed]
  14. Pharmacokinetics of lomefloxacin in patients with cirrhosis. Lebrec, D., Gaudin, C., Benhamou, J.P. Am. J. Med. (1992) [Pubmed]
  15. Comparative penetration of lomefloxacin and other quinolones into human phagocytes. Perea, E.J., García, I., Pascual, A. Am. J. Med. (1992) [Pubmed]
  16. Different effects of products containing metal ions on the absorption of lomefloxacin. Lehto, P., Kivistö, K.T. Clin. Pharmacol. Ther. (1994) [Pubmed]
  17. Molecular responses to photogenotoxic stress induced by the antibiotic lomefloxacin in human skin cells: from DNA damage to apoptosis. Marrot, L., Belaïdi, J.P., Jones, C., Perez, P., Riou, L., Sarasin, A., Meunier, J.R. J. Invest. Dermatol. (2003) [Pubmed]
  18. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Wise, R., Andrews, J.M., Ashby, J.P., Matthews, R.S. Antimicrob. Agents Chemother. (1988) [Pubmed]
  19. Comparison of the safety and efficacy of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infections: results from a multicenter study. Andrade-Villanueva, J., Flores-Gaxiola, A., Lopez-Guillen, P., Aguirre-Avalos, G., Morfin-Otero, R., Rodriguez-Noriega, E. Am. J. Med. (1992) [Pubmed]
  20. A multicenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery. Klimberg, I.W., Childs, S.J., Madore, R.J., Klimberg, S.R. Am. J. Med. (1992) [Pubmed]
  21. The phototumorigenic fluoroquinolone, lomefloxacin, photosensitises p53 accumulation and transcriptional activity in human skin cells. Kidd, S., Meunier, J.R., Traynor, N.J., Marrot, L., Agapakis-Causse, C., Gibbs, N.K. J. Photochem. Photobiol. B, Biol. (2000) [Pubmed]
  22. Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study. Cazzola, M., Matera, M.G., Tufano, M.A., Catalanotti, P., Polverino, M., Cantoni, V., Fici, F., Sarlo, F., Rossi, F. Journal of chemotherapy (Florence, Italy) (2001) [Pubmed]
  23. Effects of lomefloxacin and norfloxacin on pancreatic beta-cell ATP-sensitive K(+) channels. Zünkler, B.J., Wos, M. Life Sci. (2003) [Pubmed]
  24. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function. Nilsen, O.G., Saltvedt, E., Walstad, R.A., Marstein, S. Am. J. Med. (1992) [Pubmed]
  25. Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study. Grassi, C., Albera, C., Pozzi, E. Am. J. Med. (1992) [Pubmed]
  26. Lomefloxacin concentrations in bone after a single oral dose. On, A., Nightingale, C.H., Quintiliani, R., Sweeney, K.R., Pasternak, H.S., Maderazo, E.G. Am. J. Med. (1992) [Pubmed]
WikiGenes - Universities